Oncotelic (OTLC) CEO Trieu Vuong Buys $15,013 in Stock

AI Summary

Trieu Vuong, CEO of Oncotelic Therapeutics (OTLC), purchased $15,013 worth of the company's stock. This transaction demonstrates Vuong's confidence in the company's future prospects. Insider purchases can signal to the market that key executives believe the stock is undervalued. Such actions may influence investor sentiment and impact trading activity in the stock.